Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | PPIB | P23284 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498104 | 1.00 | L3MBTL1 (0.46) | L3MBTL1LMNANPSR1HTTHTR2A | |
| Hydrochloric Acid SCHEMBL6600350 | 0.98 | L3MBTL1 (0.45) | L3MBTL1LMNANPSR1HTTHTR2A | |
| SCHEMBL6629689 | 0.81 | SIGMAR1 (0.53) | NPSR1HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL6227380 | 0.81 | POLB (0.46) | L3MBTL1LMNAHTTPOLBALDH1A1 | |
| SCHEMBL6112888 | 0.79 | SIGMAR1 (0.46) | HTR2AHTR2CHTR2BSIGMAR1POLB | |
| SCHEMBL5610431 | 0.74 | L3MBTL1 (0.44) | L3MBTL1LMNANPSR1HTTHTR2A | |
| SCHEMBL29661169 | 0.74 | NPSR1 (0.50) | L3MBTL1LMNANPSR1HTTHTR2A | |
| SCHEMBL1745254 | 0.74 | NPSR1 (0.50) | L3MBTL1LMNANPSR1HTTHTR2A | |
| SCHEMBL6806743 | 0.73 | L3MBTL1 (0.40) | L3MBTL1LMNANPSR1HTTHTR2A | |
| SCHEMBL2592743 | 0.71 | HTR2A (0.36) | HTR2ASIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113825499-B | Percutaneous absorption preparation containing high-dose donepezil or salt thereof | 株式会社大熊制药 | 2024-03-08 | — | — | CN | disclosed |
| US-20220226296-A1 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-21 | — | — | US | disclosed |
| EP-3970704-A1 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | Daewoong Pharmaceutical Co., Ltd. (KR) | 2022-03-23 | — | — | EP | disclosed |
| WO-2010070511-A3 | A PROCESS FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE | ALEMBIC LIMITED (IN) | 2011-10-13 | — | — | WO | disclosed |
| EP-2370408-A2 | A PROCESS FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE | Alembic Limited (IN) | 2011-10-05 | — | — | EP | disclosed |
| US-20110123929-A1 | OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, PRODUCTION METHOD FOR THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT | FUJIFILM CORPORATION (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| WO-2010070511-A2 | A PROCESS FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE | ALEMBIC LIMITED (IN) | 2010-06-24 | — | — | WO | disclosed |
| EP-2116527-A1 | OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, METHOD FOR PRODUCTION OF THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT | FUJIFILM Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-5349090-A | Process for preparing arylketoamines | HOECHST CELANESE CORPORATION (US) | 1994-09-20 | — | — | US | disclosed |
| US-5338884-A | Reacting an arylisonitrosoalkanone with hydrogen then acid, ester inpresence of catalyst | HOECHST CELANESE (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0586479-A1 | DIHYDROXYINDANONE TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5220063-A | Reacting arylisonitrosoalkanone with hydrogen and acyl doner in presence of transition metal catalyst | HOECHST CELANESE CORPORATION (US) | 1993-06-15 | — | — | US | disclosed |
| US-5198585-A | Catalytic hydrogenation of arylisonitrosoalkanone | HOECHST CELANESE CORPORATION (US) | 1993-03-30 | — | — | US | disclosed |
| WO-1993001158-A1 | METHOD FOR THE PREPARATION OF ARYLKETOAMINES | HOECHST CELANESE CORPORATION (US) | 1993-01-21 | — | — | WO | disclosed |
| US-5175368-A | Hydrogenating aryl alpha-oximinoalkyl ketones in aqueous medium containing hydrochlroic acid, recovering salt | HOECHST CELANESE CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0491557-A1 | Process for the preparation of arylalkylamines and substituted arylalkylamines | HOECHST CELANESE CORPORATION (US) | 1992-06-24 | — | — | EP | disclosed |
| EP-0481705-A1 | Process for the preparation of arylalkylamines and substituted arylalkylamines | HOECHST CELANESE CORPORATION (US) | 1992-04-22 | — | — | EP | disclosed |
| US-5041669-A | Reacting alkyl aryl ketones with alkyl nitrites, extracting product, catalytically hydrogenating/reducing in nonaqueous acid mixture | HOECHST CELANESE CORPORATION (US) | 1991-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123929-A1 | OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, PRODUCTION METHOD FOR THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT | PPOX, CRY2, HCCS | L3MBTL1 3025/4885LMNA 3886/4885NPSR1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.